Items where Subject is "WE 500-600 Muscles and tendons"

Erdos, J. and Sehic, O. and Wild, C. (2021): ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies. AIHTA Policy Brief 001/ 1. Update.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.

Goetz, G. and De Villiers, C. (2019): Allograft for anterior and posterior cruciate ligament reconstruction. Decision Support Document 116.

Jeindl, R. and Riegelnegg, M. (2023): Robot-assisted rehabilitation for incomplete spinal cord injury. Rapid Review Nr.: 005.

Mayer-Ferbas, J. and Jeindl, R. (2026): Infiltration therapies for musculoskeletal pain: intradermal whealing. Rapid Review Nr.: 020.

Wild, C. (2020): Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years. AIHTA Policy Brief 001.